• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PAREXEL honored with 2013 "Partnership Pioneers of the Year" Award

PAREXEL honored with 2013 "Partnership Pioneers of the Year" Award

April 29, 2013
CenterWatch Staff

PAREXEL International, a global biopharmaceutical services provider, has been named a recipient of the 2013 "Partnership Pioneers of the Year" award in recognition of its innovative strategic partnership with Pfizer and ICON.

Given by the advisory board of the Institute for International Research and Partnerships in Clinical Trials, the award recognizes two or more companies engaged in a partnership that moves beyond the traditional transactional model to further drug development.

"PAREXEL is honored to receive the 'Partnership Pioneers of the Year' award in recognition of our successful collaboration with Pfizer, which has ushered in an innovative approach to clinical trial execution," said Josef von Rickenbach, chairman and CEO of PAREXEL. "We are proud of our ability to utilize PAREXEL's global resources and worldwide technology infrastructure to implement high-quality clinical trials with greater efficiency. We will continue to apply lessons learned from this relationship model to drive value creation and improve outcomes-focused partnerships across our entire portfolio."

PAREXEL announced a five-year strategic partnership model with Pfizer in May 2011. The goal of the strategic partnership model is to increase the speed and efficiency of clinical development programs, while ensuring that quality, innovation and global reach are central to improving predictability of clinical trials.

"Our new alliance partner model is providing a solid foundation for integrated quality clinical services," said Dr. John Hubbard, senior vice president of development operations for Pfizer. "ICON and PAREXEL's clinical expertise and innovative technology continue to set the standard for best practices in their field. This award recognizes progress toward our goal of creating a common culture dedicated to improving clinical trial implementation. We look forward to deepening our relationship with ICON and PAREXEL, to achieve our partnership's full potential, and ultimately deliver medicines to patients in need more quickly and efficiently."

The Partnership Pioneers of the Year award comes on the heels of a new PAREXEL research report titled, Strategic Partnerships 2013. The report explores the current outsourcing landscape and examines the value that strategic partnerships provide to biopharmaceutical companies of all sizes.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing